Galmed PharmaceuticalsEOCN
13F holders, Q3 2024 (September 30)10holders
$6.84avg. 13F price*
At the end of Q3 2024, 10 institutions reported holding Galmed Pharmaceuticals Ltd. (EOCN) in their 13F filings. The largest holders were UBS Group AG ($36K), Tower Research Capital LLC (TRC) ($1K) and Morgan Stanley ($713).
- Company
- Galmed Pharmaceuticals Ltd.
- CUSIP
- M47238148
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $1K |
| Exits | 0 | $0 |
Ownership 10 holders
| UBS Group AG | 0.00% | Add +20506.0% | 5,267 | $36K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 173 | $1K |
| Morgan Stanley | 0.00% | Reduce -96.8% | 104 | $713 |
| Wells Fargo & Company | 0.00% | Reduce -3.3% | 18 | $123 |
| Federation des caisses Desjardins du Quebec | 0.00% | Reduce -8.2% | 14 | $96 |
| Osaic Holdings, Inc. | 0.00% | Add +3.3% | 5 | $34 |
| Allworth Financial LP | 0.00% | Add +28.9% | 2 | $14 |
| BNP Paribas Financial Markets | 0.00% | New | 1 | $7 |
| Elevation Wealth Partners, LLC | 0.00% | Add +56.5% | 1 | $7 |
| Tsfg, LLC | 0.00% | Reduce -6.9% | 17 | $0 |
"% of holder's portfolio" is EOCN's weight in each manager's 13F, not the share of Galmed Pharmaceuticals Ltd. the manager owns.